126 related articles for article (PubMed ID: 17970386)
21. Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee.
Carter D; Vogan A; Haji Ali Afzali H
Appl Health Econ Health Policy; 2016 Aug; 14(4):401-407. PubMed ID: 26818196
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoeconomics.
Hughes DA
Br J Clin Pharmacol; 2012 Jun; 73(6):968-72. PubMed ID: 22360714
[TBL] [Abstract][Full Text] [Related]
23. Health visitor. Briefing published by NICE.
Community Pract; 2014 Nov; 87(11):4. PubMed ID: 25612400
[No Abstract] [Full Text] [Related]
24. The Office of Fair Trading report: a prescription for value-based drug pricing.
Minhas R; Moon JC
J R Soc Med; 2007 May; 100(5):216-8. PubMed ID: 17470928
[No Abstract] [Full Text] [Related]
25. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
Dietrich ES
Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
[TBL] [Abstract][Full Text] [Related]
26. Impact of gatt agreement on drug prices.
Pillai AM
J Indian Med Assoc; 1995 Mar; 93(3):113, 120. PubMed ID: 8522810
[No Abstract] [Full Text] [Related]
27. NICE is too generous in approving drugs, analysis says.
Hawkes N
BMJ; 2015 Feb; 350():h955. PubMed ID: 25698770
[No Abstract] [Full Text] [Related]
28. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
Garpenby P
Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
[No Abstract] [Full Text] [Related]
29. How should we value future health? Was NICE right to change?
Raftery J
Value Health; 2013; 16(5):699-700. PubMed ID: 23947961
[No Abstract] [Full Text] [Related]
30. [The use of modern economic methods for the rational choice of drugs].
Khveshchuk PF; Rudakova AV; Galin AL
Voen Med Zh; 1999 Aug; 320(8):54-9. PubMed ID: 10524003
[No Abstract] [Full Text] [Related]
31. Is the Hospital Authority's drug formulary equitable and efficient?
Lau EW; Leung GM
Hong Kong Med J; 2008 Oct; 14(5):416-7. PubMed ID: 18840919
[No Abstract] [Full Text] [Related]
32. CVS and the $100,000 QALY.
Silverman E
Manag Care; 2018 Dec; 27(12):14-15. PubMed ID: 30620315
[TBL] [Abstract][Full Text] [Related]
33. Risks and benefits of importing prescription medications from lower-income countries.
Dhalla IA; Detsky AS
JAMA; 2008 Sep; 300(12):1453-5. PubMed ID: 18812537
[No Abstract] [Full Text] [Related]
34. [Introduction to pharmaco-economics: 'glossary'].
Auray JP
Therapie; 2001; 56(2):89-91. PubMed ID: 11471379
[No Abstract] [Full Text] [Related]
35. Value for money of drug regulation.
Bouvy JC; Koopmanschap MA; Schellekens H
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):247-9. PubMed ID: 22812545
[No Abstract] [Full Text] [Related]
36. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Devlin N; Parkin D
Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
[TBL] [Abstract][Full Text] [Related]
37. Can ICER bring cost-effectiveness to drug prices?
Butcher L
Manag Care; 2019 Jun; 28(6):30-33. PubMed ID: 31188097
[TBL] [Abstract][Full Text] [Related]
38. NICE Technology Appraisal No 84.
Ridley S
Anasthesiol Intensivmed Notfallmed Schmerzther; 2006 Jan; 41(1):44-6. PubMed ID: 16440263
[No Abstract] [Full Text] [Related]
39. Increasing cost of medicines.
Griffin JP
Lancet; 1993 May; 341(8853):1156-7. PubMed ID: 8097843
[No Abstract] [Full Text] [Related]
40. NICE--part 3 of 3. NICE completes the commissioning cycle.
Taylor J
Health Serv J; 2010 Mar; 120(6197):26-7. PubMed ID: 20429387
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
